Thalidomide for the treatment of patients with myelodysplastic syndromes View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2002-01-01

AUTHORS

C Strupp, U Germing, M Aivado, E Misgeld, R Haas, N Gattermann

ABSTRACT

We examined the efficacy of thalidomide in 34 patients with myelodysplastic syndromes (MDS): five RAEB-T, four RAEB, three CMML, six RARS, and 16 RA. Patients belonged to the following cytogenetic groups: 15 complex abnormal karyotypes, 12 normal karyotypes, four cases with 5q− as sole anomaly and three single aberrations. The median thalidomide dose was 400 mg/day (25/34 patients). Four patients discontinued the study after less than 5 weeks, because of fatigue (three) or skin rash (one). One patient died of heart failure after 4 weeks. In the remaining 29 patients (median follow-up: 13 months), treatment responses were classified according to the IWG criteria. Six patients (four RA, two CMML) showed progressive disease (five with transformation into AML) and four patients showed stable disease. Hematological improvement (HI) was observed in 19 patients. Nine of the responders (three RA, one RARS, two RAEB, three RAEB-T) achieved partial remission with granulocytes ⩾1500/μl, Hb > 11 g/dl and platelets ⩾100 000/μl. Four patients (one RARS, one CMML, one RAEB, one RAEB-T) had a major response, with platelet and RBC transfusion independence. Six patients (five RA, one RARS) showed minor responses (three HI-E, two HI-E+HI-P, one HI-E+HI-N). Hematological improvement occurred after a median of 2 months of thalidomide treatment. Two patients (RAEB-T) relapsed after a partial remission lasting 8 and 16 months, respectively. In summary, a therapeutic benefit was achieved in 19 of 34 study patients (56%). More... »

PAGES

1-6

References to SciGraph publications

  • 1999-11-26. Angiogenesis in myelodysplastic syndromes in BRITISH JOURNAL OF CANCER
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/sj.leu.2402330

    DOI

    http://dx.doi.org/10.1038/sj.leu.2402330

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1017710244

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/11840256


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Cardiorespiratory Medicine and Haematology", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged, 80 and over", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Anemia, Refractory", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Anemia, Refractory, with Excess of Blasts", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Blood Transfusion", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Combined Modality Therapy", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Constipation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Evaluation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Fatigue", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Leukemia, Myelomonocytic, Chronic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Myelodysplastic Syndromes", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Peripheral Nervous System Diseases", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Pilot Projects", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Remission Induction", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Thalidomide", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Treatment Outcome", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Venous Thrombosis", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany", 
              "id": "http://www.grid.ac/institutes/grid.411327.2", 
              "name": [
                "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Strupp", 
            "givenName": "C", 
            "id": "sg:person.01001653715.11", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001653715.11"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany", 
              "id": "http://www.grid.ac/institutes/grid.411327.2", 
              "name": [
                "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Germing", 
            "givenName": "U", 
            "id": "sg:person.01362464041.20", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362464041.20"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany", 
              "id": "http://www.grid.ac/institutes/grid.411327.2", 
              "name": [
                "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Aivado", 
            "givenName": "M", 
            "id": "sg:person.0760154564.99", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0760154564.99"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany", 
              "id": "http://www.grid.ac/institutes/grid.411327.2", 
              "name": [
                "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Misgeld", 
            "givenName": "E", 
            "id": "sg:person.01137007527.41", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01137007527.41"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany", 
              "id": "http://www.grid.ac/institutes/grid.411327.2", 
              "name": [
                "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Haas", 
            "givenName": "R", 
            "id": "sg:person.01127414674.14", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127414674.14"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany", 
              "id": "http://www.grid.ac/institutes/grid.411327.2", 
              "name": [
                "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Gattermann", 
            "givenName": "N", 
            "id": "sg:person.01273447501.34", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273447501.34"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/sj.bjc.6693515", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1044899602", 
              "https://doi.org/10.1038/sj.bjc.6693515"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2002-01-01", 
        "datePublishedReg": "2002-01-01", 
        "description": "We examined the efficacy of thalidomide in 34 patients with myelodysplastic syndromes (MDS): five RAEB-T, four RAEB, three CMML, six RARS, and 16 RA. Patients belonged to the following cytogenetic groups: 15 complex abnormal karyotypes, 12 normal karyotypes, four cases with 5q\u2212 as sole anomaly and three single aberrations. The median thalidomide dose was 400\u2009mg/day (25/34 patients). Four patients discontinued the study after less than 5 weeks, because of fatigue (three) or skin rash (one). One patient died of heart failure after 4 weeks. In the remaining 29 patients (median follow-up: 13 months), treatment responses were classified according to the IWG criteria. Six patients (four RA, two CMML) showed progressive disease (five with transformation into AML) and four patients showed stable disease. Hematological improvement (HI) was observed in 19 patients. Nine of the responders (three RA, one RARS, two RAEB, three RAEB-T) achieved partial remission with granulocytes \u2a7e1500/\u03bcl, Hb\u2009>\u200911\u2009g/dl and platelets \u2a7e100\u2009000/\u03bcl. Four patients (one RARS, one CMML, one RAEB, one RAEB-T) had a major response, with platelet and RBC transfusion independence. Six patients (five RA, one RARS) showed minor responses (three HI-E, two HI-E+HI-P, one HI-E+HI-N). Hematological improvement occurred after a median of 2 months of thalidomide treatment. Two patients (RAEB-T) relapsed after a partial remission lasting 8 and 16 months, respectively. In summary, a therapeutic benefit was achieved in 19 of 34 study patients (56%).", 
        "genre": "article", 
        "id": "sg:pub.10.1038/sj.leu.2402330", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1097065", 
            "issn": [
              "0887-6924", 
              "1476-5551"
            ], 
            "name": "Leukemia", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "16"
          }
        ], 
        "keywords": [
          "hematological improvement", 
          "myelodysplastic syndrome", 
          "partial remission", 
          "efficacy of thalidomide", 
          "median thalidomide dose", 
          "RBC transfusion independence", 
          "treatment of patients", 
          "complex abnormal karyotype", 
          "stable disease", 
          "study patients", 
          "skin rash", 
          "progressive disease", 
          "transfusion independence", 
          "heart failure", 
          "thalidomide treatment", 
          "thalidomide dose", 
          "IWG criteria", 
          "minor response", 
          "treatment response", 
          "therapeutic benefit", 
          "patients", 
          "abnormal karyotype", 
          "cytogenetic groups", 
          "sole anomaly", 
          "normal karyotype", 
          "major response", 
          "RAEB", 
          "remission", 
          "single aberration", 
          "syndrome", 
          "disease", 
          "weeks", 
          "months", 
          "platelets", 
          "treatment", 
          "rash", 
          "response", 
          "thalidomide", 
          "CMML", 
          "karyotype", 
          "responders", 
          "dl", 
          "dose", 
          "granulocytes", 
          "median", 
          "efficacy", 
          "RAR", 
          "days", 
          "Hb", 
          "improvement", 
          "failure", 
          "group", 
          "aberrations", 
          "fatigue", 
          "RA", 
          "criteria", 
          "cases", 
          "summary", 
          "study", 
          "benefits", 
          "anomalies", 
          "independence"
        ], 
        "name": "Thalidomide for the treatment of patients with myelodysplastic syndromes", 
        "pagination": "1-6", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1017710244"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/sj.leu.2402330"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "11840256"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/sj.leu.2402330", 
          "https://app.dimensions.ai/details/publication/pub.1017710244"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-09-02T15:50", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_359.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1038/sj.leu.2402330"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.leu.2402330'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.leu.2402330'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.leu.2402330'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.leu.2402330'


     

    This table displays all metadata directly associated to this object as RDF triples.

    246 TRIPLES      21 PREDICATES      109 URIs      100 LITERALS      28 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/sj.leu.2402330 schema:about N12db6e6ec0b843eab0594fd7cd657d51
    2 N15d7e62851c84bca9ae44dfa0adc2dba
    3 N204a97cd127f4d0089f08642957d9e9f
    4 N239fbf78cdb243f19c6e74df38efcb61
    5 N2b1b14840a8242b1aed9018f0ca738b0
    6 N2bd2693a57b34803971ffd7f78d4ac2e
    7 N36d106165b09491ea200699f68431074
    8 N37139643447b45d1a80361be2cccace3
    9 N552829344b35495baf7167509d15828e
    10 N58923767af1c4f81a10aa69ebd16fa3d
    11 N64a293f7d144489aa6dc6e56671bdabb
    12 N6f7b6a03bc694472b9e4fdf1c5ade215
    13 N777f53a9e89647a088834555a79e6208
    14 N7809993842114b3a8e105fa2638bac47
    15 N8cc2da9cafb5474d92aa8cdcab745443
    16 Na4dd0c848a254cbbbc36ebe5dfe5eff4
    17 Nbe23451e33ce4732807b944e20799c1a
    18 Nc27693dddab44f908d1472d07a9b916f
    19 Needc5b9aa67c4b45ad2b588acd6d4215
    20 Nfd06f65b514e4743aed562c510b6aebd
    21 Nff47cedde9254699ba51161764c9bb5c
    22 anzsrc-for:11
    23 anzsrc-for:1102
    24 schema:author Nadac7d3a790f4f528b6e17a9f9302efa
    25 schema:citation sg:pub.10.1038/sj.bjc.6693515
    26 schema:datePublished 2002-01-01
    27 schema:datePublishedReg 2002-01-01
    28 schema:description We examined the efficacy of thalidomide in 34 patients with myelodysplastic syndromes (MDS): five RAEB-T, four RAEB, three CMML, six RARS, and 16 RA. Patients belonged to the following cytogenetic groups: 15 complex abnormal karyotypes, 12 normal karyotypes, four cases with 5q− as sole anomaly and three single aberrations. The median thalidomide dose was 400 mg/day (25/34 patients). Four patients discontinued the study after less than 5 weeks, because of fatigue (three) or skin rash (one). One patient died of heart failure after 4 weeks. In the remaining 29 patients (median follow-up: 13 months), treatment responses were classified according to the IWG criteria. Six patients (four RA, two CMML) showed progressive disease (five with transformation into AML) and four patients showed stable disease. Hematological improvement (HI) was observed in 19 patients. Nine of the responders (three RA, one RARS, two RAEB, three RAEB-T) achieved partial remission with granulocytes ⩾1500/μl, Hb > 11 g/dl and platelets ⩾100 000/μl. Four patients (one RARS, one CMML, one RAEB, one RAEB-T) had a major response, with platelet and RBC transfusion independence. Six patients (five RA, one RARS) showed minor responses (three HI-E, two HI-E+HI-P, one HI-E+HI-N). Hematological improvement occurred after a median of 2 months of thalidomide treatment. Two patients (RAEB-T) relapsed after a partial remission lasting 8 and 16 months, respectively. In summary, a therapeutic benefit was achieved in 19 of 34 study patients (56%).
    29 schema:genre article
    30 schema:isAccessibleForFree false
    31 schema:isPartOf N6f2e43f106f949c99529e130fffa37b6
    32 Nd7518d06970e43c78e38beb7046e0a1d
    33 sg:journal.1097065
    34 schema:keywords CMML
    35 Hb
    36 IWG criteria
    37 RA
    38 RAEB
    39 RAR
    40 RBC transfusion independence
    41 aberrations
    42 abnormal karyotype
    43 anomalies
    44 benefits
    45 cases
    46 complex abnormal karyotype
    47 criteria
    48 cytogenetic groups
    49 days
    50 disease
    51 dl
    52 dose
    53 efficacy
    54 efficacy of thalidomide
    55 failure
    56 fatigue
    57 granulocytes
    58 group
    59 heart failure
    60 hematological improvement
    61 improvement
    62 independence
    63 karyotype
    64 major response
    65 median
    66 median thalidomide dose
    67 minor response
    68 months
    69 myelodysplastic syndrome
    70 normal karyotype
    71 partial remission
    72 patients
    73 platelets
    74 progressive disease
    75 rash
    76 remission
    77 responders
    78 response
    79 single aberration
    80 skin rash
    81 sole anomaly
    82 stable disease
    83 study
    84 study patients
    85 summary
    86 syndrome
    87 thalidomide
    88 thalidomide dose
    89 thalidomide treatment
    90 therapeutic benefit
    91 transfusion independence
    92 treatment
    93 treatment of patients
    94 treatment response
    95 weeks
    96 schema:name Thalidomide for the treatment of patients with myelodysplastic syndromes
    97 schema:pagination 1-6
    98 schema:productId N5ef0361c6d8441ea839afd92910dba92
    99 N6c352b3525ae4c9cb9e28a1449e27bbf
    100 Nc574e1606bb54da7b5aed3f6669b3cde
    101 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017710244
    102 https://doi.org/10.1038/sj.leu.2402330
    103 schema:sdDatePublished 2022-09-02T15:50
    104 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    105 schema:sdPublisher N8195b1b4e31444ff83bab4a58be5cd54
    106 schema:url https://doi.org/10.1038/sj.leu.2402330
    107 sgo:license sg:explorer/license/
    108 sgo:sdDataset articles
    109 rdf:type schema:ScholarlyArticle
    110 N0dc22e4d2ce442f98b22d936a9cb2b2d rdf:first sg:person.01273447501.34
    111 rdf:rest rdf:nil
    112 N12db6e6ec0b843eab0594fd7cd657d51 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    113 schema:name Female
    114 rdf:type schema:DefinedTerm
    115 N15d7e62851c84bca9ae44dfa0adc2dba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    116 schema:name Aged
    117 rdf:type schema:DefinedTerm
    118 N204a97cd127f4d0089f08642957d9e9f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    119 schema:name Leukemia, Myelomonocytic, Chronic
    120 rdf:type schema:DefinedTerm
    121 N239fbf78cdb243f19c6e74df38efcb61 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    122 schema:name Treatment Outcome
    123 rdf:type schema:DefinedTerm
    124 N2b1b14840a8242b1aed9018f0ca738b0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    125 schema:name Anemia, Refractory
    126 rdf:type schema:DefinedTerm
    127 N2bd2693a57b34803971ffd7f78d4ac2e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    128 schema:name Humans
    129 rdf:type schema:DefinedTerm
    130 N36d106165b09491ea200699f68431074 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    131 schema:name Drug Evaluation
    132 rdf:type schema:DefinedTerm
    133 N37139643447b45d1a80361be2cccace3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    134 schema:name Venous Thrombosis
    135 rdf:type schema:DefinedTerm
    136 N3b20afaab73a41568ed12aedf7a842c6 rdf:first sg:person.01137007527.41
    137 rdf:rest N717fafceb1d54128bd53c1e59ce96772
    138 N4114e8f45f2d478faadcc78c1e151f0b rdf:first sg:person.01362464041.20
    139 rdf:rest Ne4c64072ec6f4a548bab3a984dbd426b
    140 N552829344b35495baf7167509d15828e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    141 schema:name Remission Induction
    142 rdf:type schema:DefinedTerm
    143 N58923767af1c4f81a10aa69ebd16fa3d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    144 schema:name Combined Modality Therapy
    145 rdf:type schema:DefinedTerm
    146 N5ef0361c6d8441ea839afd92910dba92 schema:name doi
    147 schema:value 10.1038/sj.leu.2402330
    148 rdf:type schema:PropertyValue
    149 N64a293f7d144489aa6dc6e56671bdabb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    150 schema:name Anemia, Refractory, with Excess of Blasts
    151 rdf:type schema:DefinedTerm
    152 N6c352b3525ae4c9cb9e28a1449e27bbf schema:name dimensions_id
    153 schema:value pub.1017710244
    154 rdf:type schema:PropertyValue
    155 N6f2e43f106f949c99529e130fffa37b6 schema:issueNumber 1
    156 rdf:type schema:PublicationIssue
    157 N6f7b6a03bc694472b9e4fdf1c5ade215 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    158 schema:name Middle Aged
    159 rdf:type schema:DefinedTerm
    160 N717fafceb1d54128bd53c1e59ce96772 rdf:first sg:person.01127414674.14
    161 rdf:rest N0dc22e4d2ce442f98b22d936a9cb2b2d
    162 N777f53a9e89647a088834555a79e6208 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    163 schema:name Constipation
    164 rdf:type schema:DefinedTerm
    165 N7809993842114b3a8e105fa2638bac47 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    166 schema:name Thalidomide
    167 rdf:type schema:DefinedTerm
    168 N8195b1b4e31444ff83bab4a58be5cd54 schema:name Springer Nature - SN SciGraph project
    169 rdf:type schema:Organization
    170 N8cc2da9cafb5474d92aa8cdcab745443 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    171 schema:name Pilot Projects
    172 rdf:type schema:DefinedTerm
    173 Na4dd0c848a254cbbbc36ebe5dfe5eff4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    174 schema:name Male
    175 rdf:type schema:DefinedTerm
    176 Nadac7d3a790f4f528b6e17a9f9302efa rdf:first sg:person.01001653715.11
    177 rdf:rest N4114e8f45f2d478faadcc78c1e151f0b
    178 Nbe23451e33ce4732807b944e20799c1a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    179 schema:name Peripheral Nervous System Diseases
    180 rdf:type schema:DefinedTerm
    181 Nc27693dddab44f908d1472d07a9b916f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    182 schema:name Myelodysplastic Syndromes
    183 rdf:type schema:DefinedTerm
    184 Nc574e1606bb54da7b5aed3f6669b3cde schema:name pubmed_id
    185 schema:value 11840256
    186 rdf:type schema:PropertyValue
    187 Nd7518d06970e43c78e38beb7046e0a1d schema:volumeNumber 16
    188 rdf:type schema:PublicationVolume
    189 Ne4c64072ec6f4a548bab3a984dbd426b rdf:first sg:person.0760154564.99
    190 rdf:rest N3b20afaab73a41568ed12aedf7a842c6
    191 Needc5b9aa67c4b45ad2b588acd6d4215 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    192 schema:name Aged, 80 and over
    193 rdf:type schema:DefinedTerm
    194 Nfd06f65b514e4743aed562c510b6aebd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    195 schema:name Blood Transfusion
    196 rdf:type schema:DefinedTerm
    197 Nff47cedde9254699ba51161764c9bb5c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    198 schema:name Fatigue
    199 rdf:type schema:DefinedTerm
    200 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    201 schema:name Medical and Health Sciences
    202 rdf:type schema:DefinedTerm
    203 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
    204 schema:name Cardiorespiratory Medicine and Haematology
    205 rdf:type schema:DefinedTerm
    206 sg:journal.1097065 schema:issn 0887-6924
    207 1476-5551
    208 schema:name Leukemia
    209 schema:publisher Springer Nature
    210 rdf:type schema:Periodical
    211 sg:person.01001653715.11 schema:affiliation grid-institutes:grid.411327.2
    212 schema:familyName Strupp
    213 schema:givenName C
    214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001653715.11
    215 rdf:type schema:Person
    216 sg:person.01127414674.14 schema:affiliation grid-institutes:grid.411327.2
    217 schema:familyName Haas
    218 schema:givenName R
    219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127414674.14
    220 rdf:type schema:Person
    221 sg:person.01137007527.41 schema:affiliation grid-institutes:grid.411327.2
    222 schema:familyName Misgeld
    223 schema:givenName E
    224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01137007527.41
    225 rdf:type schema:Person
    226 sg:person.01273447501.34 schema:affiliation grid-institutes:grid.411327.2
    227 schema:familyName Gattermann
    228 schema:givenName N
    229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273447501.34
    230 rdf:type schema:Person
    231 sg:person.01362464041.20 schema:affiliation grid-institutes:grid.411327.2
    232 schema:familyName Germing
    233 schema:givenName U
    234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362464041.20
    235 rdf:type schema:Person
    236 sg:person.0760154564.99 schema:affiliation grid-institutes:grid.411327.2
    237 schema:familyName Aivado
    238 schema:givenName M
    239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0760154564.99
    240 rdf:type schema:Person
    241 sg:pub.10.1038/sj.bjc.6693515 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044899602
    242 https://doi.org/10.1038/sj.bjc.6693515
    243 rdf:type schema:CreativeWork
    244 grid-institutes:grid.411327.2 schema:alternateName Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany
    245 schema:name Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany
    246 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...